Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Metformin  COVID-19 treatment studies for Metformin  C19 studies: Metformin  Metformin   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 22% Improvement Relative Risk Shestakova et al. Metformin for COVID-19 Prophylaxis Is prophylaxis with metformin beneficial for COVID-19? Retrospective 189,998 patients in Russia (March 2020 - November 2021) Lower mortality with metformin (p=0.0012) Shestakova et al., Frontiers in Endocrinology, doi:10.3389/fendo.2022.909874 Favors metformin Favors control
Risk factors for COVID-19 case fatality rate in people with type 1 and type 2 diabetes mellitus: A nationwide retrospective cohort study of 235,248 patients in the Russian Federation
Shestakova et al., Frontiers in Endocrinology, doi:10.3389/fendo.2022.909874
Shestakova et al., Risk factors for COVID-19 case fatality rate in people with type 1 and type 2 diabetes mellitus: A nationwide.., Frontiers in Endocrinology, doi:10.3389/fendo.2022.909874
Aug 2022   Source   PDF  
  All Studies   Meta
Retrospective 224,190 type 2 diabetes patients in Russia, showing lower mortality with metformin use.
risk of death, 21.6% lower, RR 0.78, p = 0.001, treatment 21,471 of 139,637 (15.4%), control 12,721 of 50,361 (25.3%), adjusted per study, odds ratio converted to relative risk, Table S2, multivariable.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Shestakova et al., 9 Aug 2022, retrospective, Russia, peer-reviewed, 6 authors, study period 20 March, 2020 - 25 November, 2021.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperMetforminAll
Abstract: TYPE Original Research PUBLISHED 09 August 2022 DOI 10.3389/fendo.2022.909874 OPEN ACCESS EDITED BY Fariba Ahmadizar, University Medical Center Utrecht, Netherlands REVIEWED BY Anu Grover, Ipca Laboratories, India Sergi Trias-Llimós, Autonomous University of Barcelona, Spain Vadim Klimontov, Russian Academy of Sciences (RAS), Russia *CORRESPONDENCE O. K. Vikulova Risk factors for COVID-19 case fatality rate in people with type 1 and type 2 diabetes mellitus: A nationwide retrospective cohort study of 235,248 patients in the Russian Federation M. V. Shestakova, O. K. Vikulova *, A. R. Elfimova, A. A. Deviatkin, I. I. Dedov and N. G. Mokrysheva Endocrinology Research Centre, Moscow, Russia SPECIALTY SECTION This article was submitted to Clinical Diabetes, a section of the journal Frontiers in Endocrinology RECEIVED 31 March 2022 ACCEPTED 28 June 2022 PUBLISHED 09 August 2022 The aim: To study the association of demographic, clinical, and laboratory factors and the use of glucose-lowering drugs and anti-coronavirus disease (COVID-19) vaccination with the COVID-19-related case fatality rate (CFR) in diabetes mellitus (DM) patients. CITATION Shestakova MV, Vikulova OK, Elfimova AR, Deviatkin AA, Dedov II and Mokrysheva NG (2022) Risk factors for COVID-19 case fatality rate in people with type 1 and type 2 diabetes mellitus: A nationwide retrospective cohort study of 235,248 patients in the Russian Federation. Front. Endocrinol. 13:909874. doi: 10.3389/fendo.2022.909874 COPYRIGHT © 2022 Shestakova, Vikulova, Elfimova, Deviatkin, Dedov and Mokrysheva. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. Frontiers in Endocrinology Methods: This study is a nationwide observational cohort study based on the data from the National Diabetes Register (NDR) that is the database containing online clinical information about the population with DM. The outcomes (death or recovery) for COVID-19 were registered in 235,248 patients with DM [type 1 diabetes mellitus (T1DM), n = 11,058; type 2 diabetes mellitus (T2DM), n = 224,190] from March 20, 2020, until November 25, 2021. The unadjusted odds ratio (OR) and 95% confidence interval (CI) were used to estimate the risk factors for CFR. Then the ranging of significant factors was performed and the most vulnerable groups of factors for the lethal outcome were chosen. Results: The CFR due to COVID-19 was 8.1% in T1DM and 15.3% in T2DM. Increased CFR was associated with the male population [OR = 1.25 (95% CI: 1.09–1.44) in T1DM and 1.18 (95% CI: 1.15–1.21) in T2DM], age ≥65 years [OR = 4.44 (95% CI: 3.75–5.24) in T1DM and 3.18 (95% CI: 3.09–3.26) in T2DM], DM duration ≥10 years [OR = 2.46 (95% CI: 2.06–2.95) in T1DM and 2.11 (95% CI: 2.06–2.16) in T2DM], body mass index (BMI) ≥30 kg/m2 [OR = 1.95 (95% CI: 1.52–2.50)] in T1DM, HbA1c ≥7% [OR = 1.35 (95% CI: 1.29–1.43)] in T2DM. The atherosclerotic cardiovascular disease (ASCVD) and chronic kidney disease (CKD) were associated with higher CFR in T1DM but not in T2DM. The preCOVID-19 glucose-lowering therapy in T2DM was differently..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop